Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Overexpression of Thrombomodulin in Adipose-Derived Mesenchymal Stem Cells Reduces Thrombogenic Risk and Enhances Therapeutic Efficacy.

Tanaka Y., Nakashima A., Ishiuchi N., Miyasako K., Morimoto K., Yoshida M.

Animal Study on Chronic Kidney Disease, published in J Am Soc Nephrol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Am Soc Nephrol (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
40711826
DOI
10.1681/ASN.0000000810

Abstract (original English)

Thrombomodulin on the cell surface acts as an anticoagulant and antifibrinolytic factor by binding to thrombin. Enhancement of thrombomodulin expression reduced renal infarction and pulmonary embolism induced by adipose-derived mesenchymal stem cells. Adipose-derived mesenchymal stem cells with enhanced thrombomodulin potentiated anti-inflammation and antifibrotic effects. Adipose-derived mesenchymal stem cells (ASCs) are expected to be a new therapy for organ injury; however, they were reported to have procoagulant activity, raising concerns about thrombogenic risk. Thrombomodulin acts as an anticoagulant factor by binding to thrombin, leading to the hypothesis that ASCs overexpressing thrombomodulin (TM-ASCs) could be safely used for cell therapy by reducing the risk of thromboembolism. TM-ASCs were generated using adeno-associated virus carrying thrombomodulin cDNA. To examine the risk of ASC-induced renal infarction, ASCs were administered through renal artery into rats with unilateral ischemia-reperfusion injury (IRI) and contralateral nephrectomy. To assess the risk of ASC-induced pulmonary embolism, ASCs were injected into rats through tail vein. In addition, we examined whether TM-ASCs potently inhibited inflammatory cell infiltration and kidney fibrosis in IRI rats. Furthermore, we explored synthetic compounds that enhanced thrombomodulin expression in ASCs. Overexpres

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research